Preparation and properties of an alpha-1-protease inhibitor concentrate with high specific activity

Vox Sanguinis

Volumn 81, Issue 1, 2001, Pages 29-36

  Mattes, E ^a   Matthiessen, H P ^a   Turecek, P L ^a   Schwarz, H P ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

Alpha 1 protease inhibitor; Antitrypsin; Hydroxyapatite; Isoelectric focusing; Isoforms

Indexed keywords

ALPHA 1 ANTITRYPSIN; HYDROXYAPATITE; SEPHAROSE;

ARTICLE; CHROMATOGRAPHY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SYNTHESIS; HEATING; ISOELECTRIC FOCUSING; PRECIPITATION; PRIORITY JOURNAL; PURIFICATION; RELATIVE DENSITY; VAPOR; VIRUS INACTIVATION;

ALPHA 1-ANTITRYPSIN; BLOOD PROTEINS; CHROMATOGRAPHY, AGAROSE; HUMANS; ISOELECTRIC FOCUSING; PANCREATIC ELASTASE; PRECIPITATION; PROTEIN ISOFORMS; SERINE PROTEINASE INHIBITORS; STERILIZATION; THERAPEUTIC EQUIVALENCY; TRYPSIN INHIBITORS;

EID: 0035412643     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2001.00049.x     Document Type: Article

References (47)

1. Potempa J, Korzus E, Travis J: The serpin superfamily of proteinase inhibitors. Structure, Function and Regulation. J Biol Chem 1994; 269:15957-15960
2. Travis J, Salvesen GS: Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52:655-709
3. Norman MR, Mowat AP, Hutchison DC: Molecular basis, clinical consequences and diagnosis of alpha-1 antitrypsin deficiency. Ann Clin Biochem 1997; 34:230-246
4. Janus ED, Phillips NT, Carrell RW: Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet 1985; 1:152-154
5. Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM, Wittes JT, Crystal RG: Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316:1055-1062
6. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J: A randomized clinical trial of alpha (1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160:1468-1472
7. Wencker M, Banik N, Buhl R, Seidel R, Konietzko N: Long-term treatment of alpha(1)-antitrypsin deficiency-related pulmonary emphysema with human alpha(1)-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998; 11:428-433
8. Hutchison DSC, Hughes MD: Alpha(1)-antitrypsin replacement therapy: Will efficacy ever be proved? Eur Resp J 1997; 10:2192-2193
9. Seersholm N, Wencker M, Banik N, Viskum K, Dorksen A, Kokjensen A, Konietzko N: Does alpha(1)-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha(1)-antitrypsin deficiency? Eur Resp J 1997; 10:2260-2263
10. Wiederemann HP, Stoller JK: Lung disease due to alpha(1)-antitrypsin deficiency. Curr Opin Pulm Med 1996; 2:155-160
11. Pannell R, Johnson D, Travis J: Isolation and properties of human plasma alpha-1-proteinase inhibitor. Biochemistry 1974; 13:5439-5445
12. Glaser CB, Chamorro M, Crowley R, Karic L, Childs A, Calderon M: The isolation of alpha-1-protease inhibitor by a unique procedure designed for industrial application. Anal Biochem 1982; 124:364- 371
13. Hein RH, Van Beveren SM, Shearer MA, Coan MH, Brockway WJ: Production of alpha 1-proteinase inhibitor (human). Eur Respir J (Suppl.) 1990; 9:16s-20s
14. Burnouf T, Constans J, Clerc A, Descamps J, Martinache L, Goudemand M: Biochemical and biological properties of an alpha 1-antitrypsin concentrate. Vox Sang 1987; 52:291-297
15. Bischoff R, Speck D, Lepage P, Delatre L, Ledoux C, Brown SW, Roitsch C: Purification and biochemical characterization of recombinant alpha 1-antitrypsin variants expressed in Escherichia coli. Biochemistry 1991; 30:3464-3472
16. Kwon KS, Song M, Yu MH: Purification and characterization of alpha 1-antitrypsin secreted by recombinant yeast Saccharomyces diastaticus. J Biotechnology 1995; 42:191-195
17. Mccracken AA, Karpichev IV, Ernaga JE, Werner ED, Dillin AG, Courchesne WE: Yeast mutants deficient in ER-associated degradation of the Z variant of alpha-1-protease inhibitor. Genetics 1996; 144:1355-1362
18. Wright G, Carver A, Cottom D, Reeves D, Scott A, Simons P, Wilmut K, Garner I, Colman A: High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep. Biotechnology (N Y) 1991; 9:830-834
19. Carver A, Wright G, Cottom D, Cooper J, Dalrymple M, Temperley S, Udell M, Reeves D, Percy J, Scott A, Barrass D, Gibson Y, Jeffrey Y, Samuel C, Colman A, Garner I: Expression of human alpha 1 antitrypsin in transgenic sheep. Cytotechnology 1992; 9:77-84
20. Terashima M, Murai Y, Kawamura M, Nakanishi S, Stoltz T, Chen L, Drohan W, Rodriguez RL, Katoh S: Production of functional human alpha (1)-antitrypsin by plant cell culture. Appl Microbiol Biotechnol 1999; 52:516-523
21. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S: Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18:180-183
22. Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang JM, Brantly M, Muzyczka N, Byrne BJ, Atkinson M, Flotte TR: Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998; 95:14384-14388
23. Zern MA, Ozaki I, Duan L, Pomerantz R, Liu SL, Strayer DS: A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Ther 1999; 6:114-120
24. Horowitz ID: Alpha 1-proteinase inhibitor (human) shortage. Chest 1996; 110:1624
25. Lutes RT: Alpha (1)-proteinase inhibitor (human) shortage. Chest 1996; 110:1624-1625
26. Cohn EJ, Strong LE, Hughes WL Jr, Mulford DL, Ashworth JN, Melin M, Taylor HL: Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946; 68:459-475
27. Barrett PN, Meyer H, Wachtel I, Eibl J, Dorner F: Inactivation of hepatitis A virus in plasma products by vapor heating. Transfusion 1997; 37:215-220
28. Bieth J, Spiess B, Wermuth CG: The synthesis and analytical use of a highly sensitive and convenient substrate of elastase. Biochem Med 1974; 11:350-357
29. Travis J, Johnson D: Human alpha 1-proteinase inhibitor. Methods Enzymol 1981; 80(Part C):754-755
30. Neuhoff V, Arold N, Taube D, Ehrhardt W: Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis 1988; 9:255-262
31. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76:4350-4354
32. Lomas D, Elliott PR, Carrell RW: Commercial plasma alpha(1)-antitrypsin [Prolastin(R)] contains a conformationally inactive, latent component. Eur Resp J 1997; 10:672-675
33. Lebing WR, Chen SX: Purification of alpha1-proteinase inhibitor using novel chromatographic separation conditions. European Patent Application EP 0698615 A1 1996:1-11
34. Jeppsson JO, Lilja H, Johansson M: Isolation and characterization of two minor fractions of alpha 1-antitrypsin by high-performance liquid chromatographic chromatofocusing. J Chromatogr 1985; 327:173-177
35. Jeppsson JO, Einarsson R: Genetic variants of alpha 1-antitrypsin and hemoglobin typed by isoelectric focusing in preselected narrow pH gradients with PhastSystem. Clin Chem 1992; 38:577-580
36. Travis J, Beatty K, Wong PS, Matheson NR: Oxidation of alpha 1-proteinase inhibitor as a major, contributing factor in the development of pulmonary emphysema. Bull Eur Physiopathol Respir 1980; 16:341-352
37. Wong PS, Travis J: Isolation and properties of oxidized alpha-1-proteinase inhibitor from human rheumatoid synovial fluid. Biochem Biophys Res Commun 1980; 96:1449-1454
38. Beatty K, Bieth J, Travis J: Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem 1980; 255:3931-3934
39. Matheson NR, Janoff A, Travis J: Enzymatic oxidation of alpha-1-proteinase inhibitor in abnormal tissue turnover. Mol Cell Biochem 1982; 45:65-71
40. Tyagi SC: Role of oxidative mixed-disulfide formation in elastaseserine proteinase inhibitor (serpin) complex. Biochemistry and cell biology. Biochimie Biologie Cellulaire 1996; 74:391-401
41. Owen MC. Alpha-1-proteinase inhibitor; in: Haeberli A (ed.). Human Protein Data. Weinheim, VCH Verlags Ges. m. b. H., 1992
42. Pajdak W, Pajdak E: Detection of inhibitory inactive fraction of alpha-1-antitrypsin in human serum. Folia Histochem Cytobiol 1986; 24:169-172
43. Carrell RW, Jeppsson J-O, Vaughan L, Brennan SO, Owen MC, Boswell DR: Human alpha 1 antitrypsin: Carbohydrate attachment and sequence homology. FEBS Lett 1981; 135:301-303
44. Vaughan L, Lorier MA, Carrell RW: Alpha 1-antitrypsin microheterogeneity. Isolation and physiological significance of isoforms. Biochim Biophys Acta 1982; 701:339-345
45. Chen SX, Hammond DJ, Klos AM, Wood WD, Wydick JE, Lebing WR: Chromatographic purification of human alpha 1 proteinase inhibitor from dissolved Cohn fraction IV-1 paste. J Chromatogr A 1998; 800:207-218
46. Chen SX, Hammond DJ, Lang JM, Lebing WR: Purification of alpha 1 proteinase inhibitor from human plasma fraction IV-1 by ion exchange chromatography. Vox Sang 1998; 74:232-241
47. Glaser CB, Karic L, Cohen AB: Low pH stability of alpha-1-antititrypsin. Biochim Biophys Acta 1977; 491:325-330